Tagged with B

Philippines Stanislas Camart, President of the French Chamber of Commerce and Industry in the Philippines, discusses the chamber’s rapidly expanding membership and how they continue to evolve and adapt their services to truly add value to their members. He also discusses the unique aspects of Filipino business culture and exciting opportunities…

Mexico Fabiola Trigueros, founder and CEO at Smart Scale, explains the importance of business intelligence capabilities to undertake proper business decisions and showcases the value proposition of Smart Scale to meet the pharmaceutical industry’s needs in this area. After slowing in 2012-13, Mexico’s pharmaceutical sector is expected to grow on average…

Singapore Dedicated Vice-President of APACMed and President of B. Braun’s Asia Pacific operations, Anna Maria Braun, shares the importance of establishing a unifying platform for the industry, the company’s Vision 2020 for “Systems Partnership”, as well as the overarching vision for the company moving forward.   As regulatory conditions change on…

France AFKLM Cargo’s Director Pharma, Renate de Walle and Sales & Business Developer Manager Pharma France, Fabrice Panza speak about AFKLM Cargo recently achieved IATA Centre of Excellence for Independent Validators Pharma (CEIV) certification as a significant milestone for the airline group and another step towards their ongoing focus on innovation…

ITTM’s innovative co-founder Dr. Andreas Kremer reveals the steps his start-up is currently undertaking to restructure the world of BioIT and the presentation of medical information. Why did you personally decide a year and half ago that ITTM was going to be your next adventure, and what were your first…

Singapore The CEO of ASLAN Pharmaceuticals, Dr. Carl Firth discusses the implications surrounding the company’s imminent initial public offering on Taiwan’s stock exchange, while explaining how this move serves to position ASLAN as Singapore’s first local success story. Having just completed a pre-IPO financing round, it seems the company has many…

Mexico Eduardo Gonzalez Pier, former Vice-Minister for Integration and Development of the Health Sector, shares his perspective on current dynamics in Mexico’s public health sector and highlights how collaboration between private and public stakeholders would benefit the Mexican system as a whole. You were Vice-Minister for Integration and Development of the…

Slovakia Biogen Slovakia’s Country Director on being an innovative global biotech in Slovakia, market access in the country, and the company’s commitment to improving the lives of patients through MS, Alzheimer’s and rare disease treatments. Ms. Strapkova Boydova, you have been Country Director of Biogen Slovakia since its inception in 2006.…

Singapore As a bio-informatics connoisseur with extensive experience in the pharmaceutical and clinical research field, Human Longevity’s Chief Information Officer, Yaron Turpaz, shares his insights on the company concept, the value proposition of big data in healthcare, as well as the overarching vision for the company’s bright global future. In a…

Mexico Alvaro Angel, the recently appointed general manager of the pharmaceutical division of Bayer Mexico, provides insights into the rapidly evolving local pharma market, and documents Bayer Mexico’s ambitious growth strategy; with the affiliate already standing out as one of the most important of the group at a global level. You…

Luxembourg Founded just five years ago, the Luxembourg Pharmaceutical Association (APL) was created in response to the divergence of Luxembourg’s pharmaceutical regulatory environment with Belgium. At present, Secretary General Hendrik Kühne’s primary objective is to build a stronger dialogue and greater trust with the authorities, such that the industry can be…

Switzerland Michael Cobas Meyer of Eli Lilly Switzerland reveals how these are very exciting times for the company, particularly given an extremely rich pipeline in the areas of diabetes, oncology and bio-medicines; how the challenge will be to transition from their existing portfolio to new products; and why Lilly´s focus is…